Vagus nerve stimulation for pharmacoresistant epilepsy

Clinical symptoms with end of service

W. O. Tatum IV, J. A. Ferreira, S. R. Benbadis, L. S. Heriaud, M. Gieron, N. T. Rodgers-Neame, Fernando Vale Diaz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose. Limited capability exists to predict when vagus nerve stimulation (VNS) battery deterioration becomes significant. Initial models last 2-5 years. We evaluated the first 18 patients with pharmacoresistent epilepsy after reimplantation to examine the clinical course observed during VNS end of service (EOS). Methods. Of 72 patients with VNS, 18 patients had generator replacement. EOS was estimated based on duration of use and stimulus parameters in accordance with manufacturer guidelines. Eight males and ten females had pharmacoresistent epilepsy for a mean of 17.9 years. Thirteen with localization-related epilepsy (LRE) and 5 nonverbal patients with symptomatic generalized epilepsy (SGE) failed a mean of 11.1 antiepileptic drugs (AEDs) over 21.5 years. Seven had intracranial evaluations and five failed epilepsy surgery. Reimplantation was performed after a mean of 34.4 months. Symptoms at end of service (EOS) were addressed by postoperative survey submitted at initial reprogramming within 2 weeks of reimplantation. Stimulus parameters were compared before and after surgery. Results. Nine of thirteen (69.2%) verbal patients and 11 of 18 (61.1%) total patients had signs or symptoms prior to replacement, suggesting clinical EOS, and 4 of 18 (22.2%) failed interrogation denoting battery failure without symptoms; however, this did not reach significance (X2=0.359,p=0.54). Increased seizures were the most frequent sign in 8 of 18 (44.4%), with intensification in 7 of 18 (38.9%). Irregular stimulation was detected in 5 of 18 (27.7%), with less intense stimulation in 4 of 18 (22.2%). Painful stimulation and behavioral worsening each occurred in 2 of 18 (11.1%). A subjective improvement in function after reimplantation was noted in 12 of 13 (92.3%) verbal patients, with greater intensity and consistency. Maximally tolerated reimplant current averaged -0.56 mA less. All but one (94.4%) felt surgery should be performed before clinical EOS occurred. Conclusions. We conclude that clinical signs and symptoms may arise during VNS EOS and following replacement. Seizure increase or a change in seizure pattern was most frequently observed. The tolerated reimplant current was less than the preoperative output current in most cases. Battery replacement before EOS appears desirable from a patient perspective.

Original languageEnglish (US)
Pages (from-to)128-132
Number of pages5
JournalEpilepsy and Behavior
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Replantation
Seizures
Signs and Symptoms
Generalized Epilepsy
Partial Epilepsy
Anticonvulsants
Guidelines

Keywords

  • Electrical
  • End of service
  • Epilepsy
  • Refractory
  • Stimulation
  • Vagus nerve

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Tatum IV, W. O., Ferreira, J. A., Benbadis, S. R., Heriaud, L. S., Gieron, M., Rodgers-Neame, N. T., & Vale Diaz, F. (2004). Vagus nerve stimulation for pharmacoresistant epilepsy: Clinical symptoms with end of service. Epilepsy and Behavior, 5(1), 128-132. https://doi.org/10.1016/j.yebeh.2003.10.014

Vagus nerve stimulation for pharmacoresistant epilepsy : Clinical symptoms with end of service. / Tatum IV, W. O.; Ferreira, J. A.; Benbadis, S. R.; Heriaud, L. S.; Gieron, M.; Rodgers-Neame, N. T.; Vale Diaz, Fernando.

In: Epilepsy and Behavior, Vol. 5, No. 1, 01.02.2004, p. 128-132.

Research output: Contribution to journalArticle

Tatum IV, WO, Ferreira, JA, Benbadis, SR, Heriaud, LS, Gieron, M, Rodgers-Neame, NT & Vale Diaz, F 2004, 'Vagus nerve stimulation for pharmacoresistant epilepsy: Clinical symptoms with end of service', Epilepsy and Behavior, vol. 5, no. 1, pp. 128-132. https://doi.org/10.1016/j.yebeh.2003.10.014
Tatum IV WO, Ferreira JA, Benbadis SR, Heriaud LS, Gieron M, Rodgers-Neame NT et al. Vagus nerve stimulation for pharmacoresistant epilepsy: Clinical symptoms with end of service. Epilepsy and Behavior. 2004 Feb 1;5(1):128-132. https://doi.org/10.1016/j.yebeh.2003.10.014
Tatum IV, W. O. ; Ferreira, J. A. ; Benbadis, S. R. ; Heriaud, L. S. ; Gieron, M. ; Rodgers-Neame, N. T. ; Vale Diaz, Fernando. / Vagus nerve stimulation for pharmacoresistant epilepsy : Clinical symptoms with end of service. In: Epilepsy and Behavior. 2004 ; Vol. 5, No. 1. pp. 128-132.
@article{a829b928445745759d06c234cd0660d5,
title = "Vagus nerve stimulation for pharmacoresistant epilepsy: Clinical symptoms with end of service",
abstract = "Purpose. Limited capability exists to predict when vagus nerve stimulation (VNS) battery deterioration becomes significant. Initial models last 2-5 years. We evaluated the first 18 patients with pharmacoresistent epilepsy after reimplantation to examine the clinical course observed during VNS end of service (EOS). Methods. Of 72 patients with VNS, 18 patients had generator replacement. EOS was estimated based on duration of use and stimulus parameters in accordance with manufacturer guidelines. Eight males and ten females had pharmacoresistent epilepsy for a mean of 17.9 years. Thirteen with localization-related epilepsy (LRE) and 5 nonverbal patients with symptomatic generalized epilepsy (SGE) failed a mean of 11.1 antiepileptic drugs (AEDs) over 21.5 years. Seven had intracranial evaluations and five failed epilepsy surgery. Reimplantation was performed after a mean of 34.4 months. Symptoms at end of service (EOS) were addressed by postoperative survey submitted at initial reprogramming within 2 weeks of reimplantation. Stimulus parameters were compared before and after surgery. Results. Nine of thirteen (69.2{\%}) verbal patients and 11 of 18 (61.1{\%}) total patients had signs or symptoms prior to replacement, suggesting clinical EOS, and 4 of 18 (22.2{\%}) failed interrogation denoting battery failure without symptoms; however, this did not reach significance (X2=0.359,p=0.54). Increased seizures were the most frequent sign in 8 of 18 (44.4{\%}), with intensification in 7 of 18 (38.9{\%}). Irregular stimulation was detected in 5 of 18 (27.7{\%}), with less intense stimulation in 4 of 18 (22.2{\%}). Painful stimulation and behavioral worsening each occurred in 2 of 18 (11.1{\%}). A subjective improvement in function after reimplantation was noted in 12 of 13 (92.3{\%}) verbal patients, with greater intensity and consistency. Maximally tolerated reimplant current averaged -0.56 mA less. All but one (94.4{\%}) felt surgery should be performed before clinical EOS occurred. Conclusions. We conclude that clinical signs and symptoms may arise during VNS EOS and following replacement. Seizure increase or a change in seizure pattern was most frequently observed. The tolerated reimplant current was less than the preoperative output current in most cases. Battery replacement before EOS appears desirable from a patient perspective.",
keywords = "Electrical, End of service, Epilepsy, Refractory, Stimulation, Vagus nerve",
author = "{Tatum IV}, {W. O.} and Ferreira, {J. A.} and Benbadis, {S. R.} and Heriaud, {L. S.} and M. Gieron and Rodgers-Neame, {N. T.} and {Vale Diaz}, Fernando",
year = "2004",
month = "2",
day = "1",
doi = "10.1016/j.yebeh.2003.10.014",
language = "English (US)",
volume = "5",
pages = "128--132",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Vagus nerve stimulation for pharmacoresistant epilepsy

T2 - Clinical symptoms with end of service

AU - Tatum IV, W. O.

AU - Ferreira, J. A.

AU - Benbadis, S. R.

AU - Heriaud, L. S.

AU - Gieron, M.

AU - Rodgers-Neame, N. T.

AU - Vale Diaz, Fernando

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Purpose. Limited capability exists to predict when vagus nerve stimulation (VNS) battery deterioration becomes significant. Initial models last 2-5 years. We evaluated the first 18 patients with pharmacoresistent epilepsy after reimplantation to examine the clinical course observed during VNS end of service (EOS). Methods. Of 72 patients with VNS, 18 patients had generator replacement. EOS was estimated based on duration of use and stimulus parameters in accordance with manufacturer guidelines. Eight males and ten females had pharmacoresistent epilepsy for a mean of 17.9 years. Thirteen with localization-related epilepsy (LRE) and 5 nonverbal patients with symptomatic generalized epilepsy (SGE) failed a mean of 11.1 antiepileptic drugs (AEDs) over 21.5 years. Seven had intracranial evaluations and five failed epilepsy surgery. Reimplantation was performed after a mean of 34.4 months. Symptoms at end of service (EOS) were addressed by postoperative survey submitted at initial reprogramming within 2 weeks of reimplantation. Stimulus parameters were compared before and after surgery. Results. Nine of thirteen (69.2%) verbal patients and 11 of 18 (61.1%) total patients had signs or symptoms prior to replacement, suggesting clinical EOS, and 4 of 18 (22.2%) failed interrogation denoting battery failure without symptoms; however, this did not reach significance (X2=0.359,p=0.54). Increased seizures were the most frequent sign in 8 of 18 (44.4%), with intensification in 7 of 18 (38.9%). Irregular stimulation was detected in 5 of 18 (27.7%), with less intense stimulation in 4 of 18 (22.2%). Painful stimulation and behavioral worsening each occurred in 2 of 18 (11.1%). A subjective improvement in function after reimplantation was noted in 12 of 13 (92.3%) verbal patients, with greater intensity and consistency. Maximally tolerated reimplant current averaged -0.56 mA less. All but one (94.4%) felt surgery should be performed before clinical EOS occurred. Conclusions. We conclude that clinical signs and symptoms may arise during VNS EOS and following replacement. Seizure increase or a change in seizure pattern was most frequently observed. The tolerated reimplant current was less than the preoperative output current in most cases. Battery replacement before EOS appears desirable from a patient perspective.

AB - Purpose. Limited capability exists to predict when vagus nerve stimulation (VNS) battery deterioration becomes significant. Initial models last 2-5 years. We evaluated the first 18 patients with pharmacoresistent epilepsy after reimplantation to examine the clinical course observed during VNS end of service (EOS). Methods. Of 72 patients with VNS, 18 patients had generator replacement. EOS was estimated based on duration of use and stimulus parameters in accordance with manufacturer guidelines. Eight males and ten females had pharmacoresistent epilepsy for a mean of 17.9 years. Thirteen with localization-related epilepsy (LRE) and 5 nonverbal patients with symptomatic generalized epilepsy (SGE) failed a mean of 11.1 antiepileptic drugs (AEDs) over 21.5 years. Seven had intracranial evaluations and five failed epilepsy surgery. Reimplantation was performed after a mean of 34.4 months. Symptoms at end of service (EOS) were addressed by postoperative survey submitted at initial reprogramming within 2 weeks of reimplantation. Stimulus parameters were compared before and after surgery. Results. Nine of thirteen (69.2%) verbal patients and 11 of 18 (61.1%) total patients had signs or symptoms prior to replacement, suggesting clinical EOS, and 4 of 18 (22.2%) failed interrogation denoting battery failure without symptoms; however, this did not reach significance (X2=0.359,p=0.54). Increased seizures were the most frequent sign in 8 of 18 (44.4%), with intensification in 7 of 18 (38.9%). Irregular stimulation was detected in 5 of 18 (27.7%), with less intense stimulation in 4 of 18 (22.2%). Painful stimulation and behavioral worsening each occurred in 2 of 18 (11.1%). A subjective improvement in function after reimplantation was noted in 12 of 13 (92.3%) verbal patients, with greater intensity and consistency. Maximally tolerated reimplant current averaged -0.56 mA less. All but one (94.4%) felt surgery should be performed before clinical EOS occurred. Conclusions. We conclude that clinical signs and symptoms may arise during VNS EOS and following replacement. Seizure increase or a change in seizure pattern was most frequently observed. The tolerated reimplant current was less than the preoperative output current in most cases. Battery replacement before EOS appears desirable from a patient perspective.

KW - Electrical

KW - End of service

KW - Epilepsy

KW - Refractory

KW - Stimulation

KW - Vagus nerve

UR - http://www.scopus.com/inward/record.url?scp=1542348245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542348245&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2003.10.014

DO - 10.1016/j.yebeh.2003.10.014

M3 - Article

VL - 5

SP - 128

EP - 132

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 1

ER -